Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

NCT06154252 is registered in ClinicalTrials.gov with Cabaletta Bio as lead sponsor.

NCT NCT06154252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06154252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Lead sponsor
Cabaletta Bio
Phase
Phase 2/3
Overall status
Recruiting
Start date
December 20, 2023
Completion date
July 31, 2028
Enrollment
74 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

anti-synthetase syndrome, dermatomyositis, idiopathic inflammatory myopathy, immune-mediated necrotizing myopathy, juvenile dermatomyositis, juvenile idiopathic inflammatory myopathy (jiim), juvenile myositis, juvenile polymyositis